Publications & Posters
Scholary publications
Fibrosis
SRK-373
September 2023
Discovery on Target 2023
Discovery and Antifibrotic Activity of an Anti-LTBP-TGFβ1 Inhibitory Antibody
Spinal Muscular Atrophy
Apitegromab
June 2023
Cure SMA 2023 Annual SMA Conference
Effect of Apitegromab on Motor Function and PEDICAT and PROMIS at 36 Months in Patients with Type 2 and Nonambulatory Type 3 Spinal Muscular Atrophy: Combined Presentation of the Phase 2 TOPAZ Study
Spinal Muscular Atrophy
Apitegromab
March 2023
2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Apitegromab in SMA (TOPAZ trial): Covariates of Multiple Efficacy Endpoints From 24 Month Data
Immuno-Oncology
SRK-181
March 2023
European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Congress
Safety and efficacy results of SRK-181 (a latent TGFβ1 inhibitor) from a phase 1 trial (DRAGON trial)
Fibrosis
Platform
November 2022
American College of Toxicology Annual Meeting 2022
Selective Latent TGFβ1 Inhibitors Exhibits Improved Nonclinical Safety Profile
Immuno-Oncology
SRK-181
November 2022
Poster Hall
